The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Richard E. Nettles, Makonen Belema et al. · Nature · 2010 · 929 citations · Full text

Hcv Ns5a Inhibitor, Viral Hepatitis, Medicine +10

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

Anna S. Lok, David Gardiner, Eric Lawitz et al. · New England Journal of Medicine · 2012 · 607 citations · Full text

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota et al. · Hepatology · 2011 · 335 citations

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki et al. · Journal of Hepatology · 2012 · 235 citations

Limited Treatment Options, Viral Hepatitis, Hcv Genotype 1B +9

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

Fiona McPhee, Amy K. Sheaffer, Jacques Friborg et al. · Antimicrobial Agents and Chemotherapy · 2012 · 183 citations · Full text